CureVac任命临床肿瘤和药物开发专家Mehdi Shahidi博士为独立主任。 CureVac appoints clinical oncologist and drug development expert Dr. Mehdi Shahidi as independent director.

CureVac是MRNA技术的先驱,已任命Mehdi Shahidi博士(临床肿瘤学家和有经验的药物开发专家)担任其监督委员会的独立主任。 CureVac, a pioneer in mRNA technology, has appointed Dr. Mehdi Shahidi, a clinical oncologist and experienced drug development expert, as an independent director on its Supervisory Board. Shahidi博士目前担任Petalion治疗学首席执行官和美第西的风险伙伴。 Dr. Shahidi currently serves as CEO of Petalion Therapeutics and a Venture Partner at Medicxi. 他在行政领导、药物研制和临床肿瘤学方面的丰富经验将加强CureVac对技术创新和研发的侧重,特别是在研制新一代以转基因国家疫苗为基础的癌症疫苗方面。 His extensive experience in executive leadership, drug development, and clinical oncology will strengthen CureVac's focus on technology innovation and R&D, particularly in the development of a new generation of mRNA-based cancer vaccines.